摘要
直肠癌的新辅助治疗包括新辅助放疗、化疗、化放疗以及分子靶向治疗.新辅助治疗可以使直肠癌退缩变小,达到降期、降级的目的 ,从而提高R0切除率和保肛率,降低术后局部复发率.目前的新辅助治疗未能改善患者的远期生存.新的化疗药物及方案替代传统药物5-氟尿嘧啶、术前联合应用分子靶向药物等是近年直肠癌新辅助治疗的重要进展,其临床研究的结果值得期待.
The neoadjuvant therapy for rectal cancer included neoadjuvant radiotherapy, neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy and neoadjuvant molecular targeted therapy. Recent reports on neoadjuvant therapy clearly showed a downstaging and downgrading effect on the primary rectal cancer. The rates of R0 resection and sphincter preservation were improved and local recurrence was decreased, but the long term survival was not improved. The results of using new chemotherapeutics and molecular targeted drugs in neoadjuvant therapy for rectal cancer were expected.
出处
《肿瘤研究与临床》
CAS
2010年第7期440-442,共3页
Cancer Research and Clinic
基金
基金项目：北京市卫生系统领军人才项目（2009-1-03）
关键词
直肠肿瘤
肿瘤辅助疗法
放射疗法
化学疗法
生物疗法
Rectal neoplasms Neoadjuvant therapy Radiotherapy Chemotherapy Biological therapy
